宜明昂科作为肿瘤免疫领域的明星biotech,拥有IMM2510(PD-L1/VEGF双抗)等热门管线。但近期,宜明昂科正在将研发布局拓展至心血管领域。11月4日,宜明昂科自主研发的替达派西普(timdarpacept,IMM01)针对动脉粥样硬化适应症的临床研究申请获得NMPA受理。这标志着宜明昂科在心血管疾病治疗领域迈出了重要一步。IMM01是宜明昂科进展最快的核心资产。该药是一种靶向CD47...
Source Link宜明昂科作为肿瘤免疫领域的明星biotech,拥有IMM2510(PD-L1/VEGF双抗)等热门管线。但近期,宜明昂科正在将研发布局拓展至心血管领域。11月4日,宜明昂科自主研发的替达派西普(timdarpacept,IMM01)针对动脉粥样硬化适应症的临床研究申请获得NMPA受理。这标志着宜明昂科在心血管疾病治疗领域迈出了重要一步。IMM01是宜明昂科进展最快的核心资产。该药是一种靶向CD47...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.